Immune reconstitution inflammatory syndrome after withdrawal of Natalizumab?
Natalizumab, a humanized monoclonal antibody directed against the very late activating antigen-4, prevents lymphocyte transmigration across endothelium in multiple sclerosis (MS).1 It is undefined whether cessation of treatment carries the risk of disease exacerbation. A postwithdrawal rebound in T2...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
August 30, 2010
|
| In: |
Neurology
Year: 2010, Jahrgang: 75, Heft: 9, Pages: 831-833 |
| ISSN: | 1526-632X |
| DOI: | 10.1212/WNL.0b013e3181f07362 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1212/WNL.0b013e3181f07362 Verlag, lizenzpflichtig, Volltext: https://n.neurology.org/content/75/9/831 
|
| Verfasserangaben: | T. Lenhard, A. Biller, W. Mueller, I. Metz, J. Schönberger, B. Wildemann |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1839016159 | ||
| 003 | DE-627 | ||
| 005 | 20230710151933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230313s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1212/WNL.0b013e3181f07362 |2 doi | |
| 035 | |a (DE-627)1839016159 | ||
| 035 | |a (DE-599)KXP1839016159 | ||
| 035 | |a (OCoLC)1389807659 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Lenhard, Thorsten |d 1966- |e VerfasserIn |0 (DE-588)128743085 |0 (DE-627)70705902X |0 (DE-576)187467331 |4 aut | |
| 245 | 1 | 0 | |a Immune reconstitution inflammatory syndrome after withdrawal of Natalizumab? |c T. Lenhard, A. Biller, W. Mueller, I. Metz, J. Schönberger, B. Wildemann |
| 264 | 1 | |c August 30, 2010 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.03.2023 | ||
| 520 | |a Natalizumab, a humanized monoclonal antibody directed against the very late activating antigen-4, prevents lymphocyte transmigration across endothelium in multiple sclerosis (MS).1 It is undefined whether cessation of treatment carries the risk of disease exacerbation. A postwithdrawal rebound in T2-weighted lesional activity has been described after short-term exposure, whereas another study reported stable findings up to 14 months after discontinuation of natalizumab.2 We report a patient who developed dramatic clinical and radiologic worsening as a consequence of natalizumab withdrawal after prolonged therapy. Several features were reminiscent of an immune reconstitution inflammatory syndrome (IRIS). - - ### Case report. - - A 30-year-old woman had been diagnosed with relapsing-remitting MS in 1999 and had received glatiramer acetate and interferon-β as disease-modifying agents before natalizumab was started as escalating therapy because of continuing relapses (3-4/year; Expanded Disability Status Scale score [EDSS] 5). Natalizumab effectively reduced disease activity to 3 mild clinical events within a treatment period of almost 2 years (22 infusions). A cranial MRI 4 months after institution of therapy showed no new or active lesions (figure, A and B). In November 2008, natalizumab was discontinued because of a wish to have children. At that time, the disease was clinically stable. The patient was able to manage her everyday life with mild support and was employed half-time as an office clerk (EDSS 5). Within 9 weeks after natalizumab withdrawal, she progressively developed high-grade tetraparesis despite repeated IV steroid pulses (methylprednisolone 8.5 g in total). This coincided with multiple new T2-weighted and gadolinium-enhancing lesions in … | ||
| 700 | 1 | |a Biller, Armin |d 1975- |e VerfasserIn |0 (DE-588)128824972 |0 (DE-627)381573680 |0 (DE-576)297351184 |4 aut | |
| 700 | 1 | |a Müller, Wolf C. |d 1967- |e VerfasserIn |0 (DE-588)1075182743 |0 (DE-627)832987476 |0 (DE-576)34814184X |4 aut | |
| 700 | 1 | |a Metz, Imke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schönberger, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wildemann, Brigitte |e VerfasserIn |0 (DE-588)110203844 |0 (DE-627)510150004 |0 (DE-576)171831330 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurology |d Philadelphia, Pa. : Wolters Kluwer, 1951 |g 75(2010), 9 vom: Aug., Seite 831-833 |h Online-Ressource |w (DE-627)302718524 |w (DE-600)1491874-2 |w (DE-576)079876609 |x 1526-632X |7 nnas |a Immune reconstitution inflammatory syndrome after withdrawal of Natalizumab? |
| 773 | 1 | 8 | |g volume:75 |g year:2010 |g number:9 |g month:08 |g pages:831-833 |g extent:3 |a Immune reconstitution inflammatory syndrome after withdrawal of Natalizumab? |
| 856 | 4 | 0 | |u https://doi.org/10.1212/WNL.0b013e3181f07362 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://n.neurology.org/content/75/9/831 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230313 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 110203844 |a Wildemann, Brigitte |m 110203844:Wildemann, Brigitte |d 910000 |d 911100 |d 50000 |e 910000PW110203844 |e 911100PW110203844 |e 50000PW110203844 |k 0/910000/ |k 1/910000/911100/ |k 0/50000/ |p 6 |y j | ||
| 998 | |g 1075182743 |a Müller, Wolf C. |m 1075182743:Müller, Wolf C. |d 50000 |e 50000PM1075182743 |k 0/50000/ |p 3 | ||
| 998 | |g 128824972 |a Biller, Armin |m 128824972:Biller, Armin |d 910000 |d 911400 |e 910000PB128824972 |e 911400PB128824972 |k 0/910000/ |k 1/910000/911400/ |p 2 | ||
| 998 | |g 128743085 |a Lenhard, Thorsten |m 128743085:Lenhard, Thorsten |d 910000 |d 911100 |e 910000PL128743085 |e 911100PL128743085 |k 0/910000/ |k 1/910000/911100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1839016159 |e 4288642663 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Lenhard, Thorsten","given":"Thorsten","family":"Lenhard"},{"display":"Biller, Armin","family":"Biller","given":"Armin","role":"aut","roleDisplay":"VerfasserIn"},{"display":"Müller, Wolf C.","family":"Müller","given":"Wolf C.","role":"aut","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","role":"aut","family":"Metz","given":"Imke","display":"Metz, Imke"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Schönberger, J.","family":"Schönberger","given":"J."},{"display":"Wildemann, Brigitte","given":"Brigitte","family":"Wildemann","role":"aut","roleDisplay":"VerfasserIn"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"origin":[{"publisherPlace":"Philadelphia, Pa. ; [Erscheinungsort nicht ermittelbar] ; Hagerstown, Md.","dateIssuedKey":"1951","publisher":"Wolters Kluwer ; Ovid ; Lippincott Williams & Wilkins","dateIssuedDisp":"1951-"}],"pubHistory":["1.1951 -"],"note":["Gesehen am 12.12.23"],"title":[{"title_sort":"Neurology","title":"Neurology","subtitle":"official journal of the American Academy of Neurology"}],"disp":"Immune reconstitution inflammatory syndrome after withdrawal of Natalizumab?Neurology","recId":"302718524","part":{"text":"75(2010), 9 vom: Aug., Seite 831-833","extent":"3","issue":"9","volume":"75","pages":"831-833","year":"2010"},"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"eki":["302718524"],"issn":["1526-632X"],"zdb":["1491874-2"]}}],"name":{"displayForm":["T. Lenhard, A. Biller, W. Mueller, I. Metz, J. Schönberger, B. Wildemann"]},"recId":"1839016159","title":[{"title":"Immune reconstitution inflammatory syndrome after withdrawal of Natalizumab?","title_sort":"Immune reconstitution inflammatory syndrome after withdrawal of Natalizumab?"}],"language":["eng"],"origin":[{"dateIssuedDisp":"August 30, 2010","dateIssuedKey":"2010"}],"id":{"doi":["10.1212/WNL.0b013e3181f07362"],"eki":["1839016159"]},"note":["Gesehen am 13.03.2023"],"physDesc":[{"extent":"3 S."}]} | ||
| SRT | |a LENHARDTHOIMMUNERECO3020 | ||